271 related articles for article (PubMed ID: 12796796)
1. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
[TBL] [Abstract][Full Text] [Related]
2. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
4. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
[TBL] [Abstract][Full Text] [Related]
5. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
6. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
[TBL] [Abstract][Full Text] [Related]
7. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
[No Abstract] [Full Text] [Related]
8. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer.
Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G
Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256
[TBL] [Abstract][Full Text] [Related]
9. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
[TBL] [Abstract][Full Text] [Related]
10. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
11. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Nakane T; Nakamae H; Kamoi H; Koh H; Takeoka Y; Sakamoto E; Kanashima H; Nakamae M; Ohta K; Terada Y; Koh KR; Yamane T; Hino M
Bone Marrow Transplant; 2008 Jul; 42(1):43-9. PubMed ID: 18347569
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer.
Fisher DC; Sherrill GB; Hussein A; Rubin P; Vredenburgh JJ; Elkordy M; Ross M; Petros W; Peters WP
Bone Marrow Transplant; 1996 Jul; 18(1):193-8. PubMed ID: 8832014
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
[TBL] [Abstract][Full Text] [Related]
15. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
16. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
Brockstein BE; Smiley C; Al-Sadir J; Williams SF
Bone Marrow Transplant; 2000 Apr; 25(8):885-94. PubMed ID: 10808211
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy (CTM) for breast cancer.
Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
[TBL] [Abstract][Full Text] [Related]
18. Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation.
Ando M; Yokozawa T; Sawada J; Takaue Y; Togitani K; Kawahigashi N; Narabayashi M; Takeyama K; Tanosaki R; Mineishi S; Kobayashi Y; Watanabe T; Adachi I; Tobinai K
Bone Marrow Transplant; 2000 Jan; 25(2):185-9. PubMed ID: 10673678
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.
Ueno NT; Konoplev S; Buchholz TA; Smith T; Rondón G; Anderlini P; Giralt SA; Gajewski JL; Donato ML; Cristofanilli M; Champlin RE
Bone Marrow Transplant; 2006 May; 37(10):929-35. PubMed ID: 16565737
[TBL] [Abstract][Full Text] [Related]
20. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
